Abstract: FR-PO096
Atorvastatin vs. Rosuvastatin for Contrast-Induced Nephropathy Prevention in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials and Propensity-Score Matching
Session Information
- AKI: Epidemiology, Risk Factors, Prevention
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention
Authors
- Leelaviwat, Natnicha, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Mekraksakit, Poemlarp, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Del Rio-Pertuz, Gaspar, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Benjanuwattra, Juthipong, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Trongtorsak, Angkawipa, AMITA Health, Chicago, Illinois, United States
- Duangkham, Samapon, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Abdelnabi, Mahmoud, Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Background
Statins have been reported to prevent contrast-induced nephropathy (CIN) via various mechanisms. However, the studies that compare the effect between atorvastatin and rosuvastatin following percutaneous coronary intervention (PCI) are still lacking. We conducted a systematic review and meta-analysis to compare atorvastatin and rosuvastatin for the prevention of CIN in patients with acute coronary syndrome (ACS) undergoing PCI.
Methods
Two investigators independently searched the databases of MEDLINE and EMBASE from inception to April 28, 2022. We included randomized clinical trials (RCTs) and propensity-score-matched (PSM) studies that compared atorvastatin and rosuvastatin and the effect on CIN in patients with ACS undergoing PCI. Data from each study were combined using the random-effects model and the generic inverse-variance method.
Results
Six studies (5 RCTs and 1 PSM study) involving 2,690 patients with ACS from October 2013 to August 2020 were included in our meta-analysis. There was no statical difference between atorvastatin and rosuvastatin in preventing CIN (OR 1.2; 95% CI 0.89,1.61; I2 = 0%). However, the use of high-dose atorvastatin was associated with a decreased risk of CIN following PCI in ACS patients compared to low-dose atorvastatin (OR 0.5; 95% CI 0.29, 0.87; I2 = 0%).
Conclusion
Our meta-analysis indicated that the rate of CIN in patients with ACS undergoing PCI who received atorvastatin is not statistically different from those receiving rosuvastatin. Larger studies are needed to clarify this outcome.